

Pressmeddelande 2019-02-14

QuickCool AB: Decision to direct share issue to the European High Growth Opportunities Securitization Fund

The Board of Directors of QuickCool AB (publ) ("QuickCool"), supported by the authorization from the annual general meeting on May 3, 2018, decided a directed share issue, with exemption from the shareholders' preferential rights. The new share issue has been addressed to the European High Growth Opportunities Securitization Fund.

The purpose of the directed share issue has been to fulfil one of the terms of the financing agreement that QuickCool entered with the European High Growth Opportunities Securitization Fund. Information about the financing agreement was provided through a press release on 21 June 2018. The Board of Directors has made the assessment that the share issue is the preferred *modus operandi* for the company to meet the terms of the agreement.

Through the directed share issue, 416 667 shares will be issued which will correspond to an increase in the share capital by SEK 250 000,20. The payment of the shares will be made by offsetting the debt. For each share, SEK 0.60 will be paid, which corresponds to a total amount of SEK 250 000,20.

After registering with the Swedish Companies Registration Office, QuickCool's total share capital will amount to SEK 14 674 368 and the total number of shares to 24 457 280.

For additional information, please contact::

Fredrik Radencrantz, CEO

Phone: +46-46-286 38 40

E-mail: fredrik.radencrantz@quickcool.se

Denna information är sådan information som QuickCool AB är skyldigt att offentliggöra enligt EU:s marknadsmiss-bruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 14 februari 2019.

QuickCool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the QuickCool® SYSTEM. QuickCool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool's solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool's Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. QuickCool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to www.quickcool.se